Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization

PURPOSE: Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA class II–IV) and reduced ejection fraction. This study w...

Descripción completa

Detalles Bibliográficos
Autores principales: Langenickel, Thomas H., Jordaan, Pierre, Petruck, Jesika, Kode, Kiran, Pal, Parasar, Vaidya, Soniya, Chandra, Priya, Rajman, Iris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942489/
https://www.ncbi.nlm.nih.gov/pubmed/27083930
http://dx.doi.org/10.1007/s00228-016-2062-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942489/
https://www.ncbi.nlm.nih.gov/pubmed/27083930
http://dx.doi.org/10.1007/s00228-016-2062-9

Ejemplares similares